RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000071.xml
PDF herunterladen
Semin Neurol 2016; 36(06): 586-600
DOI: 10.1055/s-0036-1592139
DOI: 10.1055/s-0036-1592139
Review Article
Optimizing Medication Outcomes in Neurocritical Care: Focus on Clinical Pharmacology
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
01. Dezember 2016 (online)
Abstract
Drug dosing in neurocritically ill patients presents enormous challenges for clinicians due to the complex pathophysiological alterations. These alterations are dynamic both between and within patients. Unpredictable exposure from standard dosing regimens, which were extrapolated to intensive care unit patients from healthy volunteer studies, may influence medication outcomes. Knowledge of potential alterations in pharmacokinetics/pharmacodynamics in these patients could be applied to maximize the clinical response and minimize adverse effects. Recognizing potential confounding clinical and treatment factors affecting drug response is an important step, but it is not enough. Overcoming absorption and distribution challenges by using specialized formulations and delivery systems is an area of active research. Improved methods for measuring drug concentrations in clinical settings across different matrices are also needed. Even with these advances, defining endogenous mediators signaling drug-target activation is necessary. Identifying biomarkers in disease and changes when a drug has reached its target will be pivotal. This information will improve our understanding of the pharmacogenomic and pharmacokinetic variables affecting pharmacodynamic endpoints across a spectrum of neurologic diseases.
-
References
- 1 Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012; 141 (5) 1327-1336
- 2 Priglinger U, Delle Karth G, Geppert A , et al. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?. Crit Care Med 2003; 31 (5) 1405-1409
- 3 Singh G, Chaudry KI, Chudler LC, Chaudry IH. Sepsis produces early depression of gut absorptive capacity: restoration with diltiazem treatment. Am J Physiol 1992; 263 (1 Pt 2): R19-R23
- 4 Tarling MM, Toner CC, Withington PS, Baxter MK, Whelpton R, Goldhill DR. A model of gastric emptying using paracetamol absorption in intensive care patients. Intensive Care Med 1997; 23 (3) 256-260
- 5 Dörffler-Melly J, de Jonge E, Pont AC , et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002; 359 (9309) 849-850
- 6 Jochberger S, Mayr V, Luckner G , et al. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of Certoparin: a prospective, clinical study. Crit Care 2005; 9 (5) R541-R548
- 7 Haas CE, Nelsen JL, Raghavendran K , et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005; 59 (6) 1336-1343 , discussion 1343–1344
- 8 Cook D, Crowther M, Meade M , et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005; 33 (7) 1565-1571
- 9 Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74 (6) 543-554
- 10 Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27 (3) 476-479
- 11 Egle H, Trittler R, Kümmerer K, Lemmen SW. Linezolid and rifampin: drug interaction contrary to expectations?. Clin Pharmacol Ther 2005; 77 (5) 451-453
- 12 van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet 2010; 49 (5) 277-294
- 13 Hernandez G, Velasco N, Wainstein C , et al. Gut mucosal atrophy after a short enteral fasting period in critically ill patients. J Crit Care 1999; 14 (2) 73-77
- 14 Maynard GA, Jones KM, Guidry JR. Phenytoin absorption from tube feedings. Arch Intern Med 1987; 147 (10) 1821
- 15 Sneed RC, Morgan WT. Interference of oral phenytoin absorption by enteral tube feedings. Arch Phys Med Rehabil 1988; 69 (9) 682-684
- 16 Oyler DR, Stump SE, Cook AM. Accuracy of nimodipine gel extraction. Neurocrit Care 2015; 22 (1) 89-92
- 17 Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: a focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 2007; 35 (9) 2196-2204
- 18 Heyland DK, Tougas G, King D, Cook DJ. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996; 22 (12) 1339-1344
- 19 Nguyen NQ, Ng MP, Chapman M, Fraser RJ, Holloway RH. The impact of admission diagnosis on gastric emptying in critically ill patients. Crit Care 2007; 11 (1) R16
- 20 Nguyen NQ, Chapman MJ, Fraser RJ , et al. The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness. Intensive Care Med 2008; 34 (3) 454-460
- 21 McArthur CJ, Gin T, McLaren IM, Critchley JA, Oh TE. Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. Intensive Care Med 1995; 21 (7) 573-576
- 22 Nguyen NQ, Fraser RJ, Bryant LK , et al. The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients. Crit Care 2007; 11 (6) R132
- 23 Ritz MA, Fraser R, Edwards N , et al. Delayed gastric emptying in ventilated critically ill patients: measurement by 13 C-octanoic acid breath test. Crit Care Med 2001; 29 (9) 1744-1749
- 24 Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009; 29 (12) 1219-1229
- 25 Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The effect of critical illness on drug distribution. Curr Pharm Biotechnol 2011; 12 (12) 2030-2036
- 26 Stephens KE, Ishizaka A, Larrick JW, Raffin TA. Tumor necrosis factor causes increased pulmonary permeability and edema. Comparison to septic acute lung injury. Am Rev Respir Dis 1988; 137 (6) 1364-1370
- 27 Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37 (3) 840-851 , quiz 859
- 28 Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16 (4) 327-330
- 29 Ronchera-Oms CL, Tormo C, Ordovás JP, Abad J, Jiménez NV. Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. J Clin Pharm Ther 1995; 20 (5) 253-258
- 30 Etzel JV, Nafziger AN, Bertino Jr JS. Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia. Antimicrob Agents Chemother 1992; 36 (3) 679-681
- 31 Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care 2011; 15 (5) R206
- 32 Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71 (3) 115-121
- 33 Rolan PE. Plasma protein binding displacement interactions—why are they still regarded as clinically important?. Br J Clin Pharmacol 1994; 37 (2) 125-128
- 34 Halliday NJ, Dundee JW, Collier PS, Loughran PG, Harper KW. Influence of plasma proteins on the onset of hypnotic action of intravenous midazolam. Anaesthesia 1985; 40 (8) 763-766
- 35 von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy 2008; 28 (11) 1391-1400
- 36 Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37 (1) 13-25
- 37 Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012; 503: 269-292
- 38 Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 2008; 4 (10) 1245-1264
- 39 Meineke I, Freudenthaler S, Hofmann U , et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002; 54 (6) 592-603
- 40 Medico CJ, Walsh P. Pharmacotherapy in the critically ill obese patient. Crit Care Clin 2010; 26 (4) 679-688
- 41 Shearer E. Critical care management of obese patients. Int Anesthesiol Clin 2013; 51 (3) 164-178
- 42 Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993; 25 (2) 103-114
- 43 Hall RI. Cardiopulmonary bypass and the systemic inflammatory response: effects on drug action. J Cardiothorac Vasc Anesth 2002; 16 (1) 83-98
- 44 Petros A, Dunne N, Mehta R , et al. The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. Anesth Analg 1995; 81 (3) 458-464
- 45 Fukuoka N, Aibiki M, Tsukamoto T, Seki K, Morita S. Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia. Resuscitation 2004; 60 (2) 225-230
- 46 Zagli G, Tarantini F, Bonizzoli M , et al. Altered pharmacology in the Intensive Care Unit patient. Fundam Clin Pharmacol 2008; 22 (5) 493-501
- 47 De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41 (14) 1135-1151
- 48 Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006; 22 (2) 255-271 , vi
- 49 Boucher BA, Rodman JH, Jaresko GS, Rasmussen SN, Watridge CB, Fabian TC. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1988; 44 (6) 675-683
- 50 Boucher BA, Kuhl DA, Fabian TC, Robertson JT. Effect of neurotrauma on hepatic drug clearance. Clin Pharmacol Ther 1991; 50 (5 Pt 1): 487-497
- 51 Anderson GD, Gidal BE, Hendryx RJ , et al. Decreased plasma protein binding of valproate in patients with acute head trauma. Br J Clin Pharmacol 1994; 37 (6) 559-562
- 52 Bauer LA, Edwards WA, Dellinger EP, Raisys VA, Brennan C. Importance of unbound phenytoin serum levels in head trauma patients. J Trauma 1983; 23 (12) 1058-1060
- 53 McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18 (4) 759-778
- 54 Harbrecht BG, Frye RF, Zenati MS, Branch RA, Peitzman AB. Cytochrome P-450 activity is differentially altered in severely injured patients. Crit Care Med 2005; 33 (3) 541-546
- 55 Haas CE, Kaufman DC, Jones CE, Burstein AH, Reiss W. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 2003; 31 (5) 1338-1346
- 56 Heinemeyer G, Roots I, Dennhardt R. Monitoring of pentobarbital plasma levels in critical care patients suffering from increased intracranial pressure. Ther Drug Monit 1986; 8 (2) 145-150
- 57 Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA. Pentobarbital pharmacokinetics in patients with severe head injury. Drug Intell Clin Pharm 1987; 21 (5) 459-463
- 58 Empey PE, Velez de Mendizabal N, Bell MJ , et al; Pediatric TBI Consortium: Hypothermia Investigators. Therapeutic hypothermia decreases phenytoin elimination in children with traumatic brain injury. Crit Care Med 2013; 41 (10) 2379-2387
- 59 Hostler D, Zhou J, Tortorici MA , et al. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. Drug Metab Dispos 2010; 38 (5) 781-788
- 60 Caldwell JE, Heier T, Wright PM , et al. Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 2000; 92 (1) 84-93
- 61 Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med 2009; 37 (3) 1101-1120
- 62 Baniasadi S, Farzanegan B, Alehashem M. Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists. Ann Intensive Care 2015; 5 (1) 44
- 63 Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18 (1) 84-112
- 64 Yoshida N, Oda Y, Nishi S , et al. Effect of barbiturate therapy on phenytoin pharmacokinetics. Crit Care Med 1993; 21 (10) 1514-1522
- 65 Gibson GA, Blouin RA, Bauer LA, Rapp RP, Tibbs PA. Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report. Ther Drug Monit 1985; 7 (2) 181-184
- 66 Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract 2013; 2013: 479730
- 67 Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem?. Crit Care Med 2008; 36 (4, Suppl) S146-S151
- 68 Urakami Y, Kimura N, Okuda M, Masuda S, Katsura T, Inui K. Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. Drug Metab Pharmacokinet 2005; 20 (3) 200-205
- 69 Ciarimboli G, Lancaster CS, Schlatter E , et al. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 2012; 18 (4) 1101-1108
- 70 Schück O. Tubular secretion of creatinine and its plasma concentration. Int J Clin Pharmacol Ther Toxicol 1990; 28 (3) 127-128
- 71 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P ; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8 (4) R204-R212
- 72 Fliser D, Laville M, Covic A , et al; Ad-hoc working group of ERBP. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant 2012; 27 (12) 4263-4272
- 73 Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37 (7) 2268-2282
- 74 Pannu N, Gibney RN. Renal replacement therapy in the intensive care unit. Ther Clin Risk Manag 2005; 1 (2) 141-150
- 75 Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34 (7) 1913-1917
- 76 Ronco C, Bellomo R, Ricci Z. Continuous renal replacement therapy in critically ill patients. Nephrol Dial Transplant 2001; 16 (Suppl. 05) 67-72
- 77 Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M. Continuous hemofiltration/hemodiafiltration in critical care. Ther Apher 2002; 6 (3) 193-198
- 78 Böhler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999; 72 (72) S24-S28
- 79 Troyanov S, Cardinal J, Geadah D , et al. Solute clearances during continuous venovenous haemofiltration at various ultrafiltration flow rates using Multiflow-100 and HF1000 filters. Nephrol Dial Transplant 2003; 18 (5) 961-966
- 80 Mercer JM, Neyens RR. Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Pharmacotherapy 2010; 30 (7) 654-660
- 81 Morbitzer KA, Jordan JD, Rhoney DH. Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. Neurocrit Care 2015; 22 (2) 258-264
- 82 Udy AA, Baptista JP, Lim NL , et al. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*. Crit Care Med 2014; 42 (3) 520-527
- 83 Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents 2010; 35 (6) 606-608
- 84 May CC, Arora S, Parli SE, Fraser JF, Bastin MT, Cook AM. Augmented renal clearance in patients with subarachnoid hemorrhage. Neurocrit Care 2015; 23 (3) 374-379
- 85 Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39 (6) 455-457
- 86 Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49 (1) 1-16
- 87 Roberts JA, Abdul-Aziz MH, Lipman J , et al; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14 (6) 498-509
- 88 Roberts JA, Webb S, Paterson D, Ho KM, Lipman J. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37 (6) 2071-2078
- 89 Plog BA, Dashnaw ML, Hitomi E , et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci 2015; 35 (2) 518-526
- 90 Cho YD, Han MH, Ahn JH , et al. Simultaneous endovascular treatment of ruptured cerebral aneurysms and vasospasm. Korean J Radiol 2015; 16 (1) 180-187
- 91 Hockel K, Diedler J, Steiner J , et al. Long-term, continuous intra-arterial nimodipine treatment of severe vasospasm following aneurysmal subarachnoid hemorrhage. World Neurosurg 2016; 88: 104-112
- 92 Iwabuchi S, Yokouchi T, Hayashi M, Uehara H, Ueda M, Samejima H. Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage - analysis of time-density curve with digital subtraction angiography. Neurol Med Chir (Tokyo) 2006; 46 (11) 535-539 , discussion 540
- 93 Ott S, Jedlicka S, Wolf S , et al. Continuous selective intra-arterial application of nimodipine in refractory cerebral vasospasm due to aneurysmal subarachnoid hemorrhage. Biomed Res Int 2014; 2014 (14) 970741
- 94 Sherif C, Wambacher B, Loyoddin M , et al. Repeated combined endovascular therapy with milrinone and nimodipine for the treatment of severe vasospasm: preliminary results. Acta Neurochir Suppl (Wien) 2015; 120: 203-207
- 95 Seker F, Hesser J, Brockmann MA , et al. Pharmacokinetic modeling of intra-arterial nimodipine therapy for subarachnoid hemorrhage-related cerebral vasospasm. Clin Neuroradiol; 2015. Epub ahead of print
- 96 Pluta RM, Butman JA, Schatlo B, Johnson DL, Oldfield EH. Subarachnoid hemorrhage and the distribution of drugs delivered into the cerebrospinal fluid. Laboratory investigation. J Neurosurg 2009; 111 (5) 1001-1007 , 1–4
- 97 Koskimäki J, Tarkia M, Ahtola-Sätilä T , et al. Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model. Biomed Res Int 2015; 2015: 715752
- 98 Hänggi D, Etminan N, Macdonald RL , et al. NEWTON: nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage. Neurocrit Care 2015; 23 (2) 274-284
- 99 Jo DH, Kim JH, Lee TG, Kim JH. Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases. Nanomedicine (Lond) 2015; 11 (7) 1603-1611
- 100 Lauzon MA, Daviau A, Marcos B, Faucheux N. Nanoparticle-mediated growth factor delivery systems: a new way to treat Alzheimer's disease. J Control Release 2015; 206: 187-205
- 101 Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010; 429 (3) 435-449
- 102 Holliday SF, Kane-Gill SL, Empey PE, Buckley MS, Smithburger PL. Interpatient variability in dexmedetomidine response: a survey of the literature. ScientificWorldJournal 2014; 2014: 805013
- 103 Jannetto PJ, Bratanow NC. Pharmacogenomic considerations in the opioid management of pain. Genome Med 2010; 2 (9) 66
- 104 Cousar JL, Conley YP, Willyerd FA , et al. Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury. Neurocrit Care 2013; 19 (2) 192-198
- 105 Voora D, Ginsburg GS. Clinical application of cardiovascular pharmacogenetics. J Am Coll Cardiol 2012; 60 (1) 9-20
- 106 Willyerd FA, Empey PE, Philbrick A , et al. Expression of ATP-binding cassette transporters B1 and C1 after severe traumatic brain injury in humans. J Neurotrauma 2016; 33 (2) 226-231
- 107 Donnelly MK, Crago EA, Conley YP , et al. 20-HETE is associated with unfavorable outcomes in subarachnoid hemorrhage patients. J Cereb Blood Flow Metab 2015; 35 (9) 1515-1522
- 108 Donnelly MK, Conley YP, Crago EA , et al. Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2015; 35 (2) 267-276
- 109 Gallek MJ, Alexander SA, Crago E , et al. Endothelin-1 gene polymorphisms influence cerebrospinal fluid endothelin-1 levels following aneurysmal subarachnoid hemorrhage. Biol Res Nurs 2015; 17 (2) 185-190
- 110 Browning M, Shear DA, Bramlett HM , et al. Levetiracetam treatment in traumatic brain injury: Operation Brain Trauma Therapy. J Neurotrauma 2016; 33 (6) 581-594
- 111 Mountney A, Bramlett HM, Dixon CE , et al. Simvastatin treatment in traumatic brain injury: Operation Brain Trauma Therapy. J Neurotrauma 2016; 33 (6) 567-580
- 112 Mondello S, Shear DA, Bramlett HM , et al. Insight into pre-clinical models of traumatic brain injury using circulating brain damage biomarkers: Operation Brain Trauma Therapy. J Neurotrauma 2016; 33 (6) 595-605
- 113 Kumar RG, Rubin JE, Berger RP, Kochanek PM, Wagner AK. Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury. Brain Behav Immun 2015; 45: 253-262
- 114 Kumar RG, Diamond ML, Boles JA , et al. Acute CSF interleukin-6 trajectories after TBI: associations with neuroinflammation, polytrauma, and outcome. Brain Behav Immun 2015; 45: 253-262
- 115 Chang MT, McCarthy JJ, Shin J. Clinical application of pharmacogenetics: focusing on practical issues. Pharmacogenomics 2015; 16 (15) 1733-1741
- 116 Hoffman JM, Haidar CE, Wilkinson MR , et al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 2014; 166C (1) 45-55
- 117 Gunnerson KJ, Shaw AD, Chawla LS , et al; Sapphire Topaz investigators. TIMP2•IGFBP7 biomarker panel accurately predicts acute kidney injury in high-risk surgical patients. J Trauma Acute Care Surg 2016; 80 (2) 243-249
- 118 Myburgh R, Hochfeld WE, Dodgen TM, Ker J, Pepper MS. Cardiovascular pharmacogenetics. Pharmacol Ther 2012; 133 (3) 280-290
- 119 Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50 (1) 1-23
- 120 Wei CY, Lee MT, Chen YT. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet 2012; 21 ((R1)) R58-R65
- 121 Papadopoulos J, Smithburger PL. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit Care Med 2010; 38 (6, Suppl) S126-S135
- 122 Empey PE. Genetic predisposition to adverse drug reactions in the intensive care unit. Crit Care Med 2010; 38 (6, Suppl) S106-S116
- 123 Zhou ZW, Chen XW, Sneed KB , et al. Clinical association between pharmacogenomics and adverse drug reactions. Drugs 2015; 75 (6) 589-631
- 124 Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998; 44 (2) 415-419
- 125 Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002; 24 (3) 379-385
- 126 Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994; 105 (2) 602-604
- 127 Peterson GM, Khoo BH, von Witt RJ. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 1991; 13 (5) 415-419
- 128 Tsai D, Lipman J, Roberts JA. Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Curr Opin Crit Care 2015; 21 (5) 412-420
- 129 De Waele JJ, Carrette S, Carlier M , et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 2014; 40 (3) 380-387
- 130 Joukhadar C, Müller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 2005; 44 (9) 895-913
- 131 Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006; 50 (7) 2455-2463
- 132 Roberts JA, Roberts MS, Robertson TA, Cross SE, Lipman J. A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis. Int J Antimicrob Agents 2008; 31 (3) 240-244
- 133 Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Müller M. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000; 28 (6) 1754-1759